Log In Sign up
The largest database of trusted experimental protocols

Pd l1 66248 1 ig

Manufactured by Proteintech
Visit Supplier
Sourced in China

PD‐L1 (66248‐1‐Ig) is a laboratory reagent used for the detection and analysis of PD-L1 (Programmed Death-Ligand 1) protein expression. It is a primary antibody that binds specifically to the PD-L1 protein.

Automatically generated - may contain errors

Lab products found in correlation

Za 0508, by ZSGB-BIO (1 mentions) Cxcl1, by Affinity Biosciences (1 mentions) Cd81 66866 1 ig, by Proteintech (1 mentions) Alix 12422 1 ap, by Proteintech (1 mentions) Pd l1, by Affinity Biosciences (1 mentions) Df6526, by Affinity Biosciences (1 mentions) Calnexin, by Abcam (1 mentions)

2 protocols using pd l1 66248 1 ig

1

Immunohistochemical Analysis of Liver Cancer Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
HCC samples were fixed in neutral formaldehyde and embedded in paraffin. Then, they were cut into 4 µm sections. Immunohistochemistry was performed on these sections using previously described methods.
14 (link) The slides were stained with primary antibodies: CD63 (OTI2G6, OriGene), S100A9 (OIT3F8, OriGene), RPRD1B (OTI1C7, OriGene), ALOX5 (OTI3F1, OriGene), PD‐L1 (66248‐1‐Ig, Proteintech), HSF1 (67189‐1‐Ig, Proteintech), RAN (67500‐1‐Ig, Proteintech), XPO1/CRM1 (D6V7N, CST), MPO (ZA‐0197, ZSGB) and CD8 (ZA‐0508, ZSGB). The slides were then imaged under a light microscope (BX63, Olympus Microsystems).
Yang S., Zheng L., Li L., Zhang J., Wang J., Zhao H., Chen Y., Liu X., Gan H., Chen J., Yan M., He C., Li K., Ding C, & Li Y. (2024). Integrative multiomics analysis identifies molecular subtypes and potential targets of hepatocellular carcinoma. Clinical and Translational Medicine, 14(6), e1727.
+ Open protocol
+ Expand
2

Comprehensive Protein Analysis of Extracellular Vesicles

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Western blotting assay was conducted as previously reported [32 (link)]. The following antibodies were used: Alix (12422-1-AP, Proteintech, Wuhan, China), TSG101 (67381-1-Ig, Proteintech), CD81 (66866-1-Ig, Proteintech), Calnexin (ab133615, Abcam, Cambridge, MA, USA), iNOS (18985-1-AP, Proteintech), ARG1 (DF6657, Affinity, Changzhou, China), PD-L1 (DF6526, Affinity), PD-L1 (66248-1-IG, Proteintech), CXCL1 (AF5403, Affinity), EED (85,322 T, CST, MA, USA), and β-actin (4970S, CST).
Wang S., Li J., Hong S., Wang N., Xu S., Yang B., Zheng Y., Zhang J., Pan B., Hu Y, & Wang Z. (2024). Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling. Journal of Experimental & Clinical Cancer Research : CR, 43, 121.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!